1. Home
  2. OGN vs ANAB Comparison

OGN vs ANAB Comparison

Compare OGN & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Organon & Co.

OGN

Organon & Co.

HOLD

Current Price

$13.72

Market Cap

1.5B

Sector

Health Care

ML Signal

HOLD

Logo AnaptysBio Inc.

ANAB

AnaptysBio Inc.

SELL

Current Price

$49.25

Market Cap

1.6B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
OGN
ANAB
Founded
1923
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.6B
IPO Year
2020
2015

Fundamental Metrics

Financial Performance
Metric
OGN
ANAB
Price
$13.72
$49.25
Analyst Decision
Hold
Strong Buy
Analyst Count
5
8
Target Price
$11.25
★ $87.25
AVG Volume (30 Days)
★ 1.9M
486.6K
Earning Date
11-09-2026
11-03-2026
Dividend Yield
★ 0.58%
N/A
EPS Growth
N/A
★ 91.02
EPS
★ 0.95
N/A
Revenue
★ $6,216,000,000.00
$234,603,000.00
Revenue This Year
N/A
$17.97
Revenue Next Year
$2.51
$36.88
P/E Ratio
$14.43
★ N/A
Revenue Growth
N/A
★ 157.01
52 Week Low
$5.69
$30.27
52 Week High
$13.79
$73.30

Technical Indicators

Market Signals
Indicator
OGN
ANAB
Relative Strength Index (RSI) 53.70 31.61
Support Level $13.46 $43.75
Resistance Level $13.77 $51.67
Average True Range (ATR) 0.04 2.24
MACD -0.00 -0.45
Stochastic Oscillator 59.09 18.66

Price Performance

Historical Comparison
OGN
ANAB

About OGN Organon & Co.

Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.

About ANAB AnaptysBio Inc.

AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

Share on Social Networks: